Table 1 Screening scenarios considered in the evaluation

From: Benefits and harms of cervical screening, triage and treatment strategies in women living with HIV

Screening and triage technology

Screening age, frequency and number of lifetime screening events

Primary VIAa

• 3 yearly, 25–50 years (9×)

Cytology, HPV triage for ASC-USb

Primary HPVa

• 3 yearly, 25–50 years (9×)

• 5 yearly, 25–50 years (6×)

• 10 yearly, 25–50 years (3×)

• 10 yearly, 30–50 years (3×)

• 10 yearly, 35–45 years (2×) ‘WHO elimination strategy’5

HPV, HPV 16/18 triagec

HPV, VIA triaged

HPV, colposcopy triage

HPV, cytology triageb

  1. aAll HPV+ women treated after assessment of eligibility for ablative treatment for same-day ablation. bHPV+ women or women with cytology > ASC-US referred to colposcopy. cHPV 16/18-positive women treated after assessment of eligibility for ablative treatment and women positive for only other high-risk HPV types are treated only if VIA triage positive. dVIA triage-positive women treated after assessment of eligibility for ablative treatment. The ‘WHO elimination strategy’ refers to the screening test, ages and frequencies assumed in the earlier analysis of the cervical cancer elimination timeline2,6.
Back to article page